Solace valued at $300M in Series B funding with Menlo Ventures

Buzzy healthcare startup Solace has secured a new round of Series B funding led by venture capital firm Menlo Ventures, according to various sources. The funding round is poised to value Solace, a company that connects patients with healthcare advocates, at over $300 million. Solace aims to raise around $40 million in this round. Established in 2022 by cofounders Jeremy Gurewitz and Sara Sargent, the firm matches Medicare patients with clinical professionals across the United States. This service is currently supported by both federal Medicare and multiple Medicare Advantage plans. As of early 2025, the company had a revenue run rate of $10 million. Solace previously raised $21 million in funds, including a Series A round led by Inspired Capital, with participation from Craft Ventures, Torch Capital, and angel investors Anne Wojcicki and Susan Wojcicki. The recent funding comes amid increasing criticism of the healthcare industry, as startups strive to simplify its complexities. Few, like Solace, are focused on direct patient engagement, whereas others emphasize the automation of healthcare payment processes. Oncology startup Thyme Care is an analogous company, having raised substantial VC funding to guide patients through cancer treatments.